BlackThorn Selected as a Fierce15 2017 Winner
- Kristen Wong
- Sep 26, 2017
- 1 min read
BlackThorn Therapeutics has been selected as one of the “Fierce 15” winners for 2017. With this designation, BlackThorn is considered one of the “up-and-coming privately-held biotech companies expected to make big waves in the industry.” The annual Fierce 15 list celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.
This year, FierceBiotech evaluated a record number of nominations submitted by readers and editors of the publication, and selected the winners based on a variety of factors, including strength of technology, partnerships, venture backers and a competitive market position. FierceBiotech’s full list of winners can be found here.
With a strong financial position, novel approach to CNS drug development, and robust pipeline of first- and best-in-class treatments, the company is well positioned to achieve its goal of becoming a leading neurobehavioral health company – and, importantly, to move toward a future where patients with neurobehavioral disorders are effectively treated.
Recent Posts
See AllEBR Systems, Inc. announced the US Food and Drug Administration (FDA) approval of EBR's WiSE cardiac resynchronisation therapy ("CRT")...
RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or...
AI platform combined with autonomous labs will accelerate discovery across every domain of science Company has raised $200M in seed...